Purple Biotech

Yahoo Finance • 21 days ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech... Full story

Yahoo Finance • last month

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cash position of $10.5 million as of Sep... Full story

Yahoo Finance • 2 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3 tri-specific antibody targeting the... Full story

Yahoo Finance • 2 months ago

Purple Biotech announces receipt of Nasdaq minimum bid price notification

* Purple Biotech Ltd (NASDAQ:PPBT [https://seekingalpha.com/symbol/PPBT]) said on Monday it received a notice from Nasdaq that its American Depositary Shares (ADSs) have been below the $1 minimum bid price required for continued listing... Full story

Yahoo Finance • 2 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

REHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and... Full story

Yahoo Finance • 4 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and... Full story

Yahoo Finance • 4 months ago

Unusual volume stocks in Friday's session

Unusual volume stocks are being observed in Friday's session. [unusualvolume] TODAY'S UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT DLTH [https://www.chartmill.com/stock/quote/DLTH/profile] 8.09% 3.06M shares of DULUTH HOLD... Full story

Yahoo Finance • 4 months ago

Friday's session: top gainers and losers

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT HOUR [https://... Full story

Yahoo Finance • 4 months ago

Let's take a look at the stocks that are in motion in today's session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT CIGL [https://www.chartmill.com/stock/quote/CIGL/profile] 91.84% CON... Full story

Yahoo Finance • 4 months ago

Top stock movements in today's session.

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] GAINERS TICKER CHANGE COMMENT CIGL [ht... Full story

Yahoo Finance • 4 months ago

Which stocks are gapping on Thursday?

In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT CIGL [https://www.chartmill.com/stoc... Full story

Yahoo Finance • 4 months ago

Purple Biotech prices $6M public offering, $12M potential via warrants; shares down

* Purple Biotech (NASDAQ:PPBT [https://seekingalpha.com/symbol/PPBT]) has priced a public offering of 6M ADSs (or pre-funded warrants) at $1/unit, each unit including a short-term warrant. * Each ADS represents 200 ordinary shares; sho... Full story

Yahoo Finance • 4 months ago

Purple Biotech Announces Pricing of Up To $18 Million Public Offering

$6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or... Full story

Yahoo Finance • 5 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody target... Full story

Yahoo Finance • 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

REHOVOT, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenviron... Full story

Yahoo Finance • 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenviro... Full story

Yahoo Finance • 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Expands pipeline withacquisition of new tri-specific antibodies Data readouts for two leadclinical programs expected in2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDA... Full story

Yahoo Finance • 3 years ago

Purple Biotech Debuts Scientific Advisory Board

Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians REHOVOT, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("P... Full story

Yahoo Finance • 3 years ago

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of... Full story

Yahoo Finance • 3 years ago

Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer

Immunorizon’s lead compound targets 5T4 antigen and conditionally activates T cells and natural killer (NK) cells Conditional activation of T cells is designed to provide a wide therapeutic index for the compound REHOVOT, Israel, Feb. 0... Full story